Application-dependent immunomodulating and antimetastatic efficacy of thymic peptides in BALB/c-mice.
The immunomodulating and antimetastatic activity of clinically approved, low molecular weight, standardized thymic peptide (TP) preparations was evaluated in BALB/c-mice. Daily applications (subcutaneously, s.c.; intraperitoneally, i.p.; intramusculary, i.m.) of two commercially available TP preparations (7 consecutive days, 10, 50 and 100 micrograms per mouse and injection) up-regulated the thymus weight and thymocyte counts as well as peripheral blood leukocyte and lymphocyte counts in liver metastases-bearing mice. The immunomodulating activity of TP application was most pronounced and statistically significant for thymus weight and counts of thymocytes, leukocytes and lymphocytes after s.c. administration of both TP preparations and concentrations. I.p. and i.m. TP-injections were less effective at reaching statistical significance, however, for defined dosages and parameters, only. To evaluate the influence of TP on experimental liver metastases, RAW 117 lymphosarcoma cells were intravenously inoculated into BALB/c-mice. TP (10, 50, 100 micrograms/mouse) were s.c., i.p. and i.m. administered daily for 7 consecutive days starting 24 hours after tumor cell challenge. Liver colonization was investigated on day 14 after tumor cell inoculation and demonstrated a statistically significant (p < 0.05) reduction of experimental liver metastases for s.c. (both preparations and concentrations) as well as i.p. and i.m. (dose-dependent) TP-treated mice.
Beuth
J
J
Institute for Scientific Evaluation of Naturopathy, University of Cologne, Robert-Koch-Str. 10, 50931 Cologne, Germany. Josef.Beuth@medizin.uni-koeln.de
Schierholz
J M
JM
Ko
H L
HL
Braun
J M
JM
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D004354:Drug Screening Assays, Antitumor; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D007273:Injections, Intramuscular; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007958:Leukocyte Count; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control / Q000556:secondary*; D018655:Lymphocyte Count; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009929:Organ Size / Q000187:drug effects; D010455:Peptides / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D015203:Reproducibility of Results; D013949:Thymus Extracts / Q000008:administration & dosage* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D013950:Thymus Gland / Q000737:chemistry* / Q000187:drug effects; D014020:Tissue Extracts / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D010455:Peptides; C062459:Thym-Uvocal; D013949:Thymus Extracts; D014020:Tissue Extracts; C451980:thymoject